Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
eseba-vec (HB-200)
i
Other names:
HB-200, HB200, HB-202/HB-201, alternating 2-vector HB-202/HB-201, HB-202/HB-201 alternating
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Hookipa Pharma
Drug class:
HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
Related drugs:
‹
Versamune HPV (1)
BNT113 (0)
CRTE7A2-01 (0)
HB-201 (0)
HPV-T (0)
ISA101 (0)
MEDI0457 (0)
NEXI-003 (0)
RTX-321 (0)
VGX-3100 (0)
TG4001 (0)
DPX-E7 (0)
E7 TCR-T (0)
KITE-439 (0)
axalimogene filolisbac (0)
TSC-200-A0201 (0)
Versamune HPV (1)
BNT113 (0)
CRTE7A2-01 (0)
HB-201 (0)
HPV-T (0)
ISA101 (0)
MEDI0457 (0)
NEXI-003 (0)
RTX-321 (0)
VGX-3100 (0)
TG4001 (0)
DPX-E7 (0)
E7 TCR-T (0)
KITE-439 (0)
axalimogene filolisbac (0)
TSC-200-A0201 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + HB-200
Sensitive: C3 – Early Trials
pembrolizumab + HB-200
Sensitive
:
C3
pembrolizumab + HB-200
Sensitive: C3 – Early Trials
pembrolizumab + HB-200
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login